Holen Sie sich die Stockscreener-App
1.66
5.14%
-0.09
Schlusskurs vom Vortag:
$1.75
Offen:
$1.75
24-Stunden-Volumen:
2.35M
Relative Volume:
1.47
Marktkapitalisierung:
$379.07M
Einnahmen:
$8.95M
Nettoeinkommen (Verlust:
$-21.49M
KGV:
-13.83
EPS:
-0.12
Netto-Cashflow:
$-29.24M
1W Leistung:
-1.78%
1M Leistung:
+37.19%
6M Leistung:
+304.88%
1J Leistung:
+96.43%
1-Tages-Spanne:
$1.63
$1.78
1-Wochen-Bereich:
$1.63
$1.83
52-Wochen-Spanne:
$0.3651
$1.83
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
Firmenname
Lineage Cell Therapeutics Inc
Sektor
Branche
Telefon
510-871-4188
Adresse
2173 Salk Avenue, Suite 200, Carlsbad, CA
Vergleichen Sie LCTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
1.66 | 399.62M | 8.95M | -21.49M | -29.24M | -0.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-20 | Eingeleitet | Craig Hallum | Buy |
| 2022-11-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-06-14 | Eingeleitet | B. Riley Securities | Buy |
| 2021-08-19 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-03-31 | Eingeleitet | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc Aktie (LCTX) Neueste Nachrichten
What the charts say about Lineage Cell Therapeutics Inc. todayJuly 2025 Volume & Weekly Market Pulse Alerts - newser.com
Analyzing drawdowns of Lineage Cell Therapeutics Inc. with statistical tools - newser.com
Why Lineage Cell Therapeutics Inc. stock remains undervaluedGap Down & Comprehensive Market Scan Insights - newser.com
How institutional ownership impacts Lineage Cell Therapeutics Inc. stockDay Trade & Breakout Confirmation Trade Signals - newser.com
Developing predictive dashboards with Lineage Cell Therapeutics Inc. data2025 Earnings Impact & Reliable Breakout Stock Forecasts - newser.com
Can Lineage Cell Therapeutics Inc. stock ride next bull market cycleWeekly Investment Report & Weekly Hot Stock Watchlists - newser.com
How Lineage Cell Therapeutics Inc. stock reacts to Fed tighteningJuly 2025 PreEarnings & Long Hold Capital Preservation Plans - newser.com
Applying sector rotation models to Lineage Cell Therapeutics Inc.Risk Management & Expert Approved Momentum Trade Ideas - newser.com
Can Lineage Cell Therapeutics Inc. stock withstand economic slowdownTrade Risk Assessment & Long-Term Safe Investment Ideas - newser.com
Lineage Cell Therapeutics Hits New 52-Week High of $1.82 - Markets Mojo
Can Lineage Cell Therapeutics Inc. stock maintain operating marginsPortfolio Return Summary & Risk Controlled Stock Pick Alerts - newser.com
Long term hold vs stop loss in Lineage Cell Therapeutics Inc.2025 Top Decliners & Smart Swing Trading Techniques - newser.com
Spinal Cord Injury Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen - Barchart.com
Stem Cell Therapy Market Forecast to 2033: Growth Driven - openPR.com
Key resistance and support levels for Lineage Cell Therapeutics Inc.2025 Growth vs Value & Low Risk Profit Maximizing Plans - newser.com
What technical models suggest about Lineage Cell Therapeutics Inc.’s comebackMarket Sentiment Report & Safe Swing Trade Setups - newser.com
Can Lineage Cell Therapeutics Inc. hit a new high this monthSell Signal & Verified Short-Term Trading Plans - newser.com
What analysts say about Lineage Cell Therapeutics Inc stockSector Rotation Strategies & Minimal Capital Growth Plans - earlytimes.in
Can momentum traders help lift Lineage Cell Therapeutics Inc.New Guidance & Community Trade Idea Sharing - newser.com
Price momentum metrics for Lineage Cell Therapeutics Inc. explained2025 Key Lessons & Weekly Top Gainers Trade List - newser.com
Is Lineage Cell Therapeutics Inc. stock cheap vs fundamentalsJuly 2025 WrapUp & Daily Profit Focused Stock Screening - newser.com
Using R and stats models for Lineage Cell Therapeutics Inc. forecastingJuly 2025 Price Swings & Community Trade Idea Sharing Platform - newser.com
Advanced analytics toolkit walkthrough for Lineage Cell Therapeutics Inc.2025 Risk Factors & AI Based Trade Execution Alerts - newser.com
Using data tools to time your Lineage Cell Therapeutics Inc. exitWeekly Trade Summary & Growth-Oriented Investment Plans - newser.com
Goldman Sachs Group Inc. Sells 34,963 Shares of Lineage Cell Therapeutics, Inc. $LCTX - Defense World
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Trading Up 4.7%Should You Buy? - MarketBeat
Lineage Cell Therapeutics Hits New 52-Week High of $1.72 - Markets Mojo
Finanzdaten der Lineage Cell Therapeutics Inc-Aktie (LCTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):